Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2025)
Avalo Therapeutics (AVTX) posted EBITDA Margin of 33461.02% for Q4 2025, down 382.65% on a QoQ basis from 6932.81% in Q4 2024, and down 2652820.0% year-over-year from N/an in Q4 2024.
Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics' EBITDA Margin history runs 10 years deep, the most recent figure standing at 33461.02% for Q4 2025.
- Quarterly EBITDA Margin fell 2652820.0% year-over-year to 33461.02% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 14585.0% (up 95105.0% YoY) and the FY2025 annual result came in at 123601.69%, down 10806609.0% from the prior year.
- EBITDA Margin was 33461.02% for Q4 2025 at Avalo Therapeutics, down from 6932.81% in the prior quarter.
- Across five years, EBITDA Margin topped out at 27.39% in Q3 2022 and bottomed at 33461.02% in Q4 2025.
- A 5-year average of 4782.2% and a median of 1588.98% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin jumped 721400 bps — and 2025, when it sank 2652820 bps.
- Avalo Therapeutics' EBITDA Margin stood at 8202.28% in 2021, then surged by 88 bps to 988.28% in 2022, then sank by 36 bps to 1341.16% in 2023, then plunged by 417 bps to 6932.81% in 2024, then tumbled by 383 bps to 33461.02% in 2025.
- Business Quant data shows AVTX's EBITDA Margin at 33461.02% in Q4 2025, 6932.81% in Q4 2024, and 5165.06% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33,461.02% |
| Dec 31, 2024 | -6,932.81% |
| Sep 30, 2024 | -5,165.06% |
| Dec 31, 2023 | -1,341.16% |
| Sep 30, 2023 | -1,588.98% |
| Jun 30, 2023 | -1,111.98% |
| Mar 31, 2023 | -1,850.95% |
| Dec 31, 2022 | -988.28% |
| Sep 30, 2022 | 27.39% |
| Jun 30, 2022 | -1,145.01% |
| Mar 31, 2022 | -1,777.75% |
| Dec 31, 2021 | -8,202.28% |
| Sep 30, 2021 | -1,219.48% |
| Jun 30, 2021 | -510.55% |
| Mar 31, 2021 | -6,465.12% |
| Dec 31, 2020 | -1,091.45% |
| Sep 30, 2020 | -1,195.05% |
| Jun 30, 2020 | -883.03% |
| Mar 31, 2020 | -1,140.63% |
| Dec 31, 2019 | -143.18% |